Lates News

Novo Nordisk (NVO.N) raised its expectations for adjusted sales and adjusted operating profit for 2026, forecasting an adjusted EBITDA growth of -6% to 0% for the fiscal year. In the second quarter of 2026, adjusted sales are expected to grow by 7% at constant exchange rates, while adjusted operating profit is expected to grow by 11% at constant exchange rates.